ASArun Swaminath

Arun Swaminath

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arun Swaminath has a total of 386 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fatigue burden and patient attribution across remission states in inflammatory bowel disease: a longitudinal cohort study

    by Arun Swaminath, Jakob Saidman, Jeremy Polman, Laura Durbin, Rachel Maggi, Troy Laurence, Keith Sultan

    Background and aims: Fatigue is common in inflammatory bowel disease (IBD), but prior work has largely focused on symptomatic disease activity rather than progressively objective remission states. We evaluated the relationship between fatigue and hierarchical remission depth, repeated changes in remission status, and patients’ attribution of fatigue to IBD. Methods: Adults with confirmed IBD completed PROMIS Fatigue surveys at 2 tertiary-care centers. PROMIS Fatigue was analyzed continuously and as clinically significant fatigue (T-score ≥55). Remission was classified hierarchically as no remission, physician-global-assessment (PGA)-defined clinical remission, endoscopic remission, or histologic remission. Visit-level repeated measures were analyzed using a linear mixed-effects model. First-visit logistic regression evaluated clinically significant fatigue after adjustment for anxiety, depression, anemia, and IBD subtype; corticosteroid exposure was added in a sensitivity model. Attribution analyses included only explicit Yes or No responses. Results: We surveyed 481 patients, contributing 900 surveys. PGA-defined clinical, endoscopic, and histologic remission remained associated with lower mean PROMIS Fatigue T-scores than no remission (adjusted differences −3.68, −3.45, and −3.27 points; all P ≤ .001). No remission remained associated with clinically significant fatigue after adjustment for anxiety, depression, anemia, IBD subtype (OR 2.75, 95% CI, 1.83-4.14), and for corticosteroid exposure (OR 2.34, 95% CI, 1.52-3.58). Attribution of fatigue to IBD differed by remission status (P < .000000001). Findings remained significant when objective remission was restricted to colonoscopy within 180 days of PROMIS completion (adjusted OR 2.23, 95% CI, 1.42-3.49). Conclusion: Remission was associated with lower fatigue burden, and patients in objective remission were less likely to attribute fatigue to IBD. These observational findings support assessing inflammatory disease control early in the evaluation of fatigue while also evaluating sleep, mood, anemia, pain, medications, and other non-inflammatory contributors.

  • Open Access

    Recurrent Ulceration and Disease at the Ileocolonic Anastomosis in Crohn’s Disease: Etiology, Prevention, and Management, a Review Article

    by Abigail Schubach, Keith Sultan, Arun Swaminath

    Ulceration at the neo-terminal ileum in patients with Crohn’s disease who have undergone previous resection remains a clinical challenge. While most patients will develop ulceration, it can be difficult to determine whether the ulceration represents a true Crohn’s recurrence. Scoring systems such as the Rutgeerts Score and modified Rutgeerts score can help differentiate between disease that may have higher risk for progression. Risk factors such as tobacco use, penetrating phenotype, and prior surgical resection have been identified, in addition to surgical technique. Recent evidence has supported certain surgical techniques, such as a side-to-side stapled technique and the Kono-S, to prevent post-surgical ulceration. Post-surgical prophylactic treatment with biologic therapies have the potential to reduce disease recurrence in certain patients. Post-surgical ulceration at the ileocolonic anastomosis is a complex problem that requires careful surveillance and evidence-based management. Understanding which patients are at high risk for disease recurrence and progression is important to guide treatment.


  • Open Access

    Analysis of the Impact of Preadmission, Inpatient, and Discharge Opioid Exposure and Dose on 30- and 90-Day Hospital Readmissions in Patients with Inflammatory Bowel Disease Exacerbations

    by Ellen A. Oseni, Miriam Blumenthal, Stephanie Izard, Michael Qiu, Anjali Mone, Arun Swaminath, Keith Sultan

    Background: Opioid use is common among patients hospitalized for inflammatory bowel disease (IBD) exacerbation and has been associated with an increased risk of readmissions. Prior studies, however, have mostly limited their analysis to hospital opioid use. This study examines opioid exposure and dosing before, during, and after hospitalization and its impact on 30- and 90-day hospital readmissions. Methods: We reviewed all adults admitted for an IBD exacerbation from 1 January 2016 to 3 January 2020, excluding pregnant patients and those with an IBD-related surgery. Use and dose of opioids before and during hospitalization and at discharge were identified through manual chart review. IBD type, demographics, and comorbidities were defined. The associations between opioid use characteristics and readmission were assessed using a series of multivariable logistic regression models. Results: Among 1062 patients meeting inclusion criteria, 191 (18.0%) were readmitted within 30 days of their index hospitalization, and 285 (26.8%) were readmitted within 90 days. Of these 1062 patients, 96 (9.02%) had preadmission opioid use, 340 (31.95%) had inpatient use, and 133 (12.50%) received a discharge opioid prescription. Preadmission, inpatient, and discharge opioid use were not associated with 30-day readmission. Preadmission and inpatient opioid use were also not associated with 90-day readmission; however, a prescription for an opioid at discharge was associated with 90-day readmission even after adjusting for confounders, OR 1.86 (1.27, 2.75), p = 0.002. On multivariable analysis, we also found that higher maximum daily dose of discharge opioids, OR 1.01 (1.00, 1.02), p = 0.037, was found to be associated with 30-day readmissions, and higher opioid doses preadmission, OR 1.01 (1.00, 1.03), p = 0.029, and at hospital discharge, OR 1.01 (1.00, 1.02), p = 0.034, were associated with increased 90-day readmission. Conclusions: Opioid prescribing at discharge poses a significant risk for readmissions. Discharge planning should emphasize minimal use of opioids at discharge.


  • Open Access

    The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program

    by Stephen B. Hanauer, Esther A. Torres, Patricia Aragon-Han, Jonathon C. Chapman, Arun C. Swaminath, Ronen Arai, Mandalina Butnariu, Thomas C. Lee, Shervin Rabizadeh, Morgan Check, et al.

    Background/Objectives: This study aimed to establish the clinical utility of a therapeutic drug monitoring (TDM)-supported, model-informed precision dosing (MIPD) approach (precision-guided dosing [PGD]) by assessing the impact of pharmacokinetic (clearance [CL]) and clinical laboratory parameters on adalimumab (ADA) dosage adjustments during maintenance therapy for inflammatory bowel disease (IBD). Methods: In the EMPOWER study, blood was collected at any time post-ADA injection. Pharmacokinetic (PK) testing was conducted in an accredited lab. Inputs for the PGD test included ADA concentrations, antibodies to ADA, albumin levels, and the current dosing regimen. CL was calculated using nonlinear mixed-effect models. Results were reported to health care providers (HCPs) within 3 days. HCPs’ treatment decisions were recorded and classified as treatment reduction, continuation, intensification, or ADA discontinuation. The physician global assessment (PGA) of disease activity was collected. Relationships between drug concentrations, CL, disease activity, and physician decision-making were assessed using logistic regression. Results: A total of 213 cases were assessed by 21 HCPs. ADA treatment was intensified in 24% and discontinued in 13% of cases. An ADA concentration ≤ 10 μg/mL was associated with a 23.7-fold and 3.0-fold higher likelihood of therapy intensification and PGA > 0, respectively, compared to concentrations > 10 μg/mL. An ADA concentration < 5 μg/mL was associated with a 3.3-fold higher likelihood of treatment discontinuation. CL ≥ 0.318 L/day was associated with a 10.4-fold higher likelihood of therapy intensification. Higher CL (>0.8 L/day) was associated with a 3.5-fold and 4.2-fold higher likelihood of treatment discontinuation and PGA > 0, respectively. Conclusions: PGD enables earlier and precise optimization of ADA dosing by predicting trough levels at any time during the therapy cycle. Optimized dosing to achieve target ADA concentrations and low clearance is crucial to mitigate therapy discontinuation and active disease in IBD patients.


  • Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis

    by Jeffrey A Lowell, Garvita Sharma, Arun Swaminath, Keith Sultan

    Background: Janus kinase (JAK) inhibitors tofacitinib and upadacitinib are effective therapies for inflammatory bowel disease and rheumatologic disorders but currently possess a warning for increased venous thromboembolism (VTE) risk. Some patients with a history of VTE may benefit from a JAK inhibitor, but the risk of recurrent VTE with JAK inhibitor use is unclear. Our goal was to observe rates of new VTE events after starting JAK inhibitor therapy in patients with a prior VTE, and observe whether concurrent anticoagulation (AC) reduces this risk. Methods: We conducted a review of adults prescribed tofacitinib or upadacitinib between January 1, 2000, and June 30, 2023, with a prior history of VTE. Patient charts were reviewed for demographic data, disease type, and VTE date(s), and to verify duration of JAK inhibitor use along with any concurrent AC. VTEs following JAK inhibitor initiation were identified by International Classification of Diseases–Tenth Revision code and verified by physician documentation and imaging. Results: We identified 79 patients with a documented VTE history before initiating JAK inhibitors, 47 of whom began a JAK inhibitor with concurrent AC. Of these, 15 patients discontinued AC while receiving JAK inhibitors. In total, 5 new VTE events were observed during 55.42 patient-years of JAK inhibitor treatment without concurrent AC (9.0 events per 100 patient-years), while no new VTE events occurred during 65.2 patient-years of JAK inhibitor treatment with concurrent AC, demonstrating a lower risk of recurrent VTE (P = .020). Conclusions: These results suggest that for patients with a prior VTE history there is a high risk for recurrent VTE while receiving JAK inhibitors. Concurrent use of AC with JAK inhibitors appears to be protective against recurrent VTEs in this population.


  • Crohn’s Disease Mortality and Ambient Air Pollution in New York City

    by Alexandra Feathers, Gina S Lovasi, Zoya Grigoryan, Kade Beem, Samit K Datta, David M Faleck, Thomas Socci, Rachel Maggi, Arun Swaminath

    Background: The worldwide increase in Crohn’s disease (CD) has accelerated alongside rising urbanization and accompanying decline in air quality. Air pollution affects epithelial cell function, modulates immune responses, and changes the gut microbiome composition. In epidemiologic studies, ambient air pollution has a demonstrated relationship with incident CD and hospitalizations. However, no data exist on the association of CD-related death and air pollution. Methods: We conducted an ecologic study comparing the number of CD-related deaths of individuals residing in given zip codes, with the level of air pollution from nitric oxide, nitrogen dioxide, sulfur dioxide (SO2), and fine particulate matter. Air pollution was measured by the New York Community Air Survey. We conducted Pearson correlations and a Poisson regression with robust standard errors. Each pollution component was modeled separately. Results: There was a higher risk of CD-related death in zip codes with higher levels of SO2 (incidence rate ratio [IRR], 1.16; 95% confidence interval [CI], 1.06-1.27). Zip codes with higher percentage of Black or Latinx residents were associated with lower CD-related death rates in the SO2 model (IRR, 0.58; 95% CI, 0.35-0.98; and IRR, 0.13; 95% CI, 0.05-0.30, respectively). There was no significant association of either population density or area-based income with the CD-related death rate. Conclusions: In New York City from 1993 to 2010, CD-related death rates were higher among individuals from neighborhoods with higher levels of SO2 but were not associated with levels of nitric oxide, nitrogen dioxide, and fine particulate matter. These findings raise an important and timely public health issue regarding exposure of CD patients to environmental SO2, warranting further exploration.


  • 946 SAFETY OF IMMUNOSUPPRESSION IN A PROSPECTIVE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS WITH A HISTORY OF CANCER: THE SAPPHIRE REGISTRY

    by Jordan E. Axelrad, Yue Jiang, Jean Frederic Colombel, Ellen J. Scherl, Dana J. Lukin, Shannon Chang, Lea Ann Chen, Seymour Katz, Joann Kwah, Arun Swaminath, et al.

  • Inflammatory bowel disease and cannabis: key counseling strategies

    by Jakob Saidman, Samantha Rubin, Arun Swaminath

    Purpose of review: Cannabis use is becoming more frequent in patients with inflammatory bowel disease (IBD). Because of the increased usage, gastroenterologists need to be cognizant of the benefits and risks associated with cannabis use in the IBD-patient population. Recent findings: Recent studies have attempted to determine whether cannabis can improve biomarkers or endoscopic findings of inflammation in patients with IBD, but the results have been inconclusive. However, cannabis has been shown to have an impact on the symptoms and quality of life of individuals with IBD. Despite these benefits, the use of cannabis in IBD is not without risks, including the potential for systemic illness, toxin ingestion and significant drug interactions. Summary: In this review article, we use a case-based approach to discuss the critical clinical data that informs us of the benefits and risks of cannabis use in IBD. The endocannabinoid system plays a crucial role in regulating various physiological functions including the gastrointestinal tract. Studies have investigated the impact of cannabis on various medical conditions, including IBD. Clinicians must be aware of the most recent data to properly educate their patients on the benefits and risks of its use.

  • Su1550: ENDOSCOPIC DISEASE ACTIVITY AND BIOLOGIC THERAPY ARE INDEPENDENT PREDICTORS OF SUBOPTIMAL BOWEL PREPARATION IN IBD PATIENTS UNDERGOING COLONOSCOPY: A MULTICENTER ANALYSIS

    by Anand Kumar, Emily Bae, Vinayak Shenoy, Megan Buckley, Laura Durbin, James Mackey, Anjali Mone, Dana J. Lukin, Arun Swaminath

  • Patient With Ulcerative Colitis and Failure of Ustekinumab Responds to Risankizumab: Similar Is Not Identical

    by Yonatan Ziv, Arun Swaminath, Keith Sultan

    To the Editors, Currently, targeted biologics for ulcerative colitis (UC) include the anti-TNF-α medications infliximab, adalimumab, golimumab, the anti-integrin vedolizumab, and ustekinumab, targeting the p40 subunits of both interleukin (IL)-12 and IL-23. New small molecule therapies include the JAK inhibitor tofacitinib and the SIP receptor modulator ozanimod. Recent guidelines on the management of nonimmune biologic failure suggest switching to a therapy with an entirely different mechanism of action.1,2 Notably, the next wave of therapies includes drugs with mechanisms either overlapping or similar to those already available. It is currently unclear whether these newer drugs might be effective rescue therapy following failure of their similar “cousin” medications. Risankizumab, a selective inhibitor to the p40 subunit of IL-23 is currently approved for the treatment of psoriasis and psoriatic arthritis. Phase 3 clinical trials of risankizumab for UC are in progress.3 It is unknown whether patients with a failure...